PTPA and neoplasm: Originally, SH‐BC‐893 was developed as an anti‐tumor agent and shown to specifically inhibit growth of Ras‐active tumor, by blocking both nutrient influx and lysosomal nutrient recycling via activation of protein phosphatase 2A (PP2A) (Kim et al,2016).